Natera reported robust Q3 2025 results, with revenue growth of 35% year-over-year driven by strong demand for its clinical products, particularly Signatera, alongside a notable improvement in gross margins.

• Revenue for the quarter reached $592 million, significantly exceeding last year’s performance.
• Clinical MRD tests exceeded 202,000, marking record growth with 21,500 additional units.
• Gross margins surged to 64.9%, reflecting efficiency gains and cost management.
• The company raised its 2025 revenue guidance by $160 million, now forecasting $2.18–$2.26 billion.
• Expanding the product offering with the new Fetal Focus test, targeting over 20 genes with positive initial feedback.